In our series, no differences between the Cryo and Fresh groups were found in short-term clinical outcomes (engraftment, acute GVHD, OS, PFS, and TRM), despite a lower CD34+ infused dose in the Cryo Group. Here, CD34 is linked to acute graft versus host disease.